Tasly Pharmaceutical's Net Profit Attributable to Parent Increases 15.63% in First Year After Integration into China Resources System

Tasly officially became a member of China Resources Sanjiu in 2025, and the market is highly focused on its integration process. The company’s annual report released on the evening of March 19 shows that the integration process exceeded market expectations in its first year, achieving operating revenue of 8.236 billion yuan in 2025; net profit attributable to shareholders was 1.105 billion yuan, a year-on-year increase of 15.63%. According to the company’s 15th Five-Year Plan, Tasly aims to double its industrial revenue and profits by the end of 2030, successfully ranking among China’s top pharmaceutical companies.

Operational Performance

Steady and Improving

The annual report indicates that the company’s performance was stable during the reporting period. The company achieved an operating revenue of 8.236 billion yuan, with its main pharmaceutical industrial business generating 7.382 billion yuan, remaining relatively stable; net profit attributable to shareholders was 1.105 billion yuan, up 15.63% year-on-year.

Among the company’s three major business segments, cardiovascular and metabolic products generated 4.067 billion yuan; neurology and mental health products brought in 1.412 billion yuan; and digestive health products contributed 986 million yuan, with a growth of 3.91%.

15th Five-Year Plan

Doubling Profits by 2030

Tasly’s annual report states that, based on stable business operations, a stable team, and stable key customers, guided by the principles of “value reshaping, business reshaping, organizational reshaping, and spirit reshaping,” the company successfully completed the critical tasks of a 100-day integration and its first-year integration. This led to the efficient integration of China Resources Sanjiu and Tasly Resources, with ongoing mutual empowerment effects, and the successful achievement of integration goals.

The annual report states that the company has established the corporate mission of “creating health for all” and the vision of “driven by innovation to become a leading enterprise in China’s pharmaceutical market.” It has systematically formulated its “15th Five-Year Plan” strategy: during this period, the company will adhere to innovation-driven development, focusing on three core therapeutic areas—cardiovascular and metabolic, neurology/mental health, and digestion—and continuously expand its pipeline of innovative products with high clinical value. By building a value cycle business model of “internal foundation-building and external enhancement,” centered on clinical value, the company will promote coordinated development and sustained growth of internal and external businesses. Through both organic growth and external expansion, it aims to double its industrial revenue (to 15 billion yuan) and profits by the end of 2030, successfully ranking among China’s top pharmaceutical companies.

To ensure the implementation of its strategy, the company will systematically execute nine major strategic initiatives, build eight core capabilities, and solidify five organizational guarantees. It will also monitor and evaluate the strategy’s implementation through management mechanisms such as business plans, management reports, and performance contracts, ensuring steady progress toward strategic goals and value realization.

External research institutions hold an optimistic view of Tasly’s future development. Cinda Securities recently reported that China Resources Sanjiu is a leader in the domestic health consumer goods sector, with industry-leading channel resources and brand capabilities. As a state-owned enterprise under China Resources, it possesses forward-looking strategic planning and market-oriented management ideas. Currently, the integration between the two parties is progressing smoothly, which is expected to bring positive changes to Tasly.

Editor | Chen Bin

Massive information, precise analysis, all on Sina Finance APP